Robocath: Company Profile

Robocath's $45M Stereotaxis Exit Caps 15 Years of Slow-Burn PCI Robotics Development

Rouen-based Robocath has spent 15 years and $57.9M building a clinically credible but commercially thin robotic platform for percutaneous coronary interventions. Its April 2026 acquisition by Stereotaxis — valued at up to $45M — represents a strategically rational outcome for a company that generated only ~€727k in FY2022 revenue despite two fielded products and CE marking in Europe. The deal pairs Robocath's mechanical robotics with Stereotaxis's magnetic navigation infrastructure, creating a combined endovascular robotics portfolio that neither company could assemble independently at comparable speed.

Business Profile

Founded in 2009 by interventional cardiologist Philippe Bencteux, MD, Robocath has operated as a founder-led, clinically oriented development company throughout its existence. The company raised $57.9M across six funding rounds — including a Series C closed April 2020 with participation from GO Capital, NCI, M Capital, and Crédit Agricole — but has not disclosed updated revenue figures since FY2022's ~€727k. With approximately 62 employees at acquisition, the organization was structurally under-resourced for global commercialization without an acquirer's distribution infrastructure.

The Stereotaxis acquisition, announced April 15, 2026, carries a headline value of up to $45M. Stereotaxis CEO David Fischel described R-One+ as the only commercially available robotic solution for PCI in Europe at the time of announcement — a positioning claim that, if accurate, represents a temporary but meaningful regulatory moat ahead of competitor launches. (MODERATE CONFIDENCE — claim originates from acquirer's public statement; independent verification of competitive landscape is limited.)

Technology

Robocath's product line spans three platforms at different maturity stages:

Product	Status	Regulatory	Key Capability
R-One	Fielded	CE Mark, China NMPA (2024)	Remote guidewire/catheter manipulation for PCI
R-One+	Fielded	CE Mark	Enhanced PCI robotics; launched mid-2023
Second-Generation Robot	Prototype / FIH Trial	Pre-approval	Bionic actuation, open architecture, telerobotics

The R-One platform reports a >98% technical success rate across multicenter studies and a company-stated meta-analysis, with no major adverse cardiac events (MACE) reported in those cohorts. (LOW CONFIDENCE — figures are company-stated; no large randomized controlled trial data has been published.) China NMPA approval, received in 2024, followed early clinical activity in the country dating to 2021.

The second-generation robot entered first-in-human (FIH) clinical trials on January 27, 2026, at Centre Cardiologique du Nord in Saint-Denis, France, enrolling 20 patients with complex coronary artery disease under principal investigator Dr. Mohammed Nejjari. Its open architecture — designed to interface with leading cath lab devices from multiple manufacturers — differentiates it from closed-ecosystem competitors and reduces hospital switching friction. A telerobotics capability for remote vascular interventions is a longer-term application vector, not a near-term commercial feature.

Clinical evidence generation has proceeded through the CHANGE registry (≥100 patients at one institution) and the R-Evolution multicenter European study. A collaborative research program with Rennes University Hospital and Philips France targets neurovascular indications, expanding the potential addressable procedure set beyond PCI.

Market Position

Robocath operates in an endovascular robotics market where TAM estimates range from $61M to $1.8B depending on methodology — a spread that reflects genuine uncertainty about procedure penetration rates and reimbursement trajectories rather than analytical disagreement. The primary competitive threat comes from Siemens Healthineers' Corindus platform (CorPath GRX), which holds FDA clearance and U.S. market presence that Robocath lacks entirely. Venture-backed challengers including Remedy Robotics, XCath, and Nanoflex are at earlier stages but represent medium-term competitive pressure in European and Asian markets.

Robocath's absence of FDA clearance or a disclosed U.S. regulatory pathway is the single largest constraint on near-term revenue potential. The Stereotaxis acquisition partially addresses this by providing an established U.S. commercial organization, but the regulatory work itself remains ahead.

Outlook

The Stereotaxis acquisition resolves Robocath's most acute problem — lack of commercial scale — but introduces integration execution risk for a 62-person team merging into a publicly traded U.S. medtech company. Key near-term catalysts include: FIH study results for the second-generation robot (expected 2026–2027), first commercial placements in China following NMPA approval, and any announcement of a U.S. FDA regulatory strategy under the Stereotaxis umbrella.

The endovascular robotics thesis is clinically sound — radiation exposure reduction for operators and remote manipulation precision are genuine unmet needs. Whether Robocath's technology, now embedded within Stereotaxis, can convert that clinical logic into repeatable hospital capital commitments at scale remains the open question after 15 years of development.